DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, for preeclampsia and acute ischemic stroke. The company also has an earlier-stage preclinical program, DM300, for severe acute pancreatitis, but its business is centered on advancing DM199 through clinical trials and regulatory review.

11.81

11.81

— DiaMedica Therapeutics Inc.
%
DM199 clinical programs100% Lead recombinant KLK1 candidate being developed for preeclampsia and acute ischemic stroke.
Preclinical pipeline0% Early-stage DM300 program targeting severe acute pancreatitis.

DiaMedica does not sell commercial products today; its near-term counterparties are clinical investigators, trial...

  • Clinical trial investigators and sitesprimary

    Run the preeclampsia and AIS studies and generate the data needed for regulatory advancement.

  • Regulatory agenciesprimary

    FDA and other agencies review pre-IND, IND, and clinical data before approval can progress.

  • Strategic partners and licensorssecondary

    May provide funding, development support, or commercialization rights for DM199.

  • Future hospitals and physiciansemerging

    Would use DM199 if approved for preeclampsia or acute ischemic stroke treatment.

The company is U.S.-based and its current business is primarily driven by clinical development and regulatory activity...

  • •Headquartered in the United States
  • •FDA interaction is central to the preeclampsia program
  • •ReMEDy2 stroke trial is being expanded globally
  • •No product revenue disclosed by country
  • •Future commercialization geography is not yet defined

DiaMedica's strategy is to advance DM199 through clinical proof-of-concept and later-stage trials in preeclampsia and...

01
Advance DM199 in preeclampsiashort-term

Preeclampsia is a new indication with potential clinical differentiation and value creation.

02
Continue and expand ReMEDy2 in AISshort-term

Stroke remains the core clinical program and a key path to eventual approval.

03
Preserve financing flexibilityshort-term

The company has no product revenue and depends on external capital to fund R&D.

04
Build optionality for commercializationmedium-term

If DM199 succeeds, the company may need a partner to support sales, manufacturing, and distribution.

DiaMedica is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, and financing dependence...

high

Clinical trial failure or non-replication of data

DM199 must show consistent efficacy and safety in later trials to support approval.

Scope
Preeclampsia and acute ischemic stroke programs
Materiality
high
high

Regulatory delay or adverse FDA feedback

The company depends on FDA review to advance from pre-IND/IND into later development.

Scope
PE program and broader clinical timeline
Materiality
high
high

Financing and dilution risk

The company has no product sales and relies on equity or other external funding.

Scope
Operating runway and ownership dilution
Materiality
high
medium

Commercialization execution risk

If approved, DiaMedica may need partners or significant internal buildout for launch.

Scope
Marketing, sales, manufacturing, distribution
Materiality
medium
medium

Government agency disruption

Reduced staffing or funding at FDA/SEC can delay approvals and normal oversight functions.

Scope
Regulatory process timing
Materiality
medium
Research and development expense recognition
Higher R&D spend can materially increase quarterly cash burn
Stock-based compensation
Affects reported operating expense and dilution analysis
Marketable securities and interest income
Changes in balances and rates affect non-operating results and liquidity
Future collaboration or licensing accounting
Could introduce revenue recognition judgments once commercialization partnerships exist

Silexion Therapeutics Corp

SLXN · Biological Products, (No Diagnostic Substances)

Damora Therapeutics, Inc.

DMRA · Pharmaceutical Preparations

MEDICINOVA INC

MNOV · Pharmaceutical Preparations

PROTHENA CORP PUBLIC LTD CO

PRTA · Pharmaceutical Preparations

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

PROKIDNEY CORP.

PROK · Biological Products, (No Diagnostic Substances)

: 28/04/2026